COCP News and Press, Cocrystal Pharma Inc. From 07/14/22

Cocrystal Pharma ( NASDAQ: COCP ) stock has risen 5.4% premarket after it said the single ascending dose portion of the Phase 1 study with its orally administered antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A had been com...

Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the singl...

BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for explorat...

If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...

BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 2...

Cocrystal Reported 1Q22 With Pipeline Updates. Cocrystal reported a 1Q22 loss of $4.2 million or $(0.04) per share. The company reviewed its recent clinical progress, including its ongoing Phase 1 study of CC-42344 in influenza and plans to initiate two Phase 1 studies of CC-45205 in COVID-19....

Cocrystal Pharma press release (NASDAQ:COCP): Q1 GAAP EPS of -$0.04 in-line. “Among our goals this year is to complete the CC-42344 Phase 1 influenza study and to initiate two Phase 1 COVID-19 studies with CDI-45205 and a novel, broad-spectrum orally administered pr...

Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A Announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the Companyȁ...

Cocrystal Pharma (COCP) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>

Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of  its 3CL protease inhibitors to treat COVID-19. The company said it applied its proprietary drug discovery platfor...